Biofidelity announced the launch of Aspyre Clinical Test for Lung for liquid biopsy samples. Aspyre Clinical Test for Lung analyzes all guideline-recommended genes for non-small cell lung cancer (NSCLC) patients in both DNA and RNA from tissue and blood within two days.
Utilizing either tissue or blood samples, Aspyre Clinical Test for Lung detects somatic mutations from DNA and gene fusions directly from RNA, maximizing the ability to identify mutations and fusions, while avoiding the extra time, additional sample requirements and added expense of running separate assays.
Data supporting the launch will be presented at the International Society of Liquid Biopsy Annual Congress, November 23-25, 2024 in Denver, Colorado during the scientific poster session.
The poster, “Aspyre Lung Blood: Validation Of A Simple, Fast and Robust Method For Molecular Profiling Of Actionable Variants In Plasma,” will be presented on Saturday, November 23, from 11am-12:30 pm Mountain. Poster Number 182 (Clinical Applications of Liquid Biopsy).
To learn more about Aspyre Clinical Test for Lung, please visit biofidelity.com/clinical-testing.
